ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Immatics NV

Immatics NV (IMTX)

10.51
-0.59
(-5.32%)
Closed March 29 04:00PM
10.51
0.00
(0.00%)
After Hours: 05:45PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
10.51
Bid
10.50
Ask
11.67
Volume
1,062,649
10.455 Day's Range 11.2182
5.90 52 Week Range 13.16
Market Cap
Previous Close
11.10
Open
11.12
Last Trade Time
Financial Volume
$ 11,604,335
VWAP
10.9202
Average Volume (3m)
536,152
Shares Outstanding
76,670,000
Dividend Yield
-
PE Ratio
21.48
Earnings Per Share (EPS)
0.49
Revenue
172.86M
Net Profit
37.51M

About Immatics NV

Immatics NV is engaged in the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeuti... Immatics NV is engaged in the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers. Show more

Sector
Health & Allied Services,nec
Industry
Health & Allied Services,nec
Headquarters
Tubingen, Deu
Founded
1970
Immatics NV is listed in the Health & Allied Services sector of the NASDAQ with ticker IMTX. The last closing price for Immatics NV was $11.10. Over the last year, Immatics NV shares have traded in a share price range of $ 5.90 to $ 13.16.

Immatics NV currently has 76,670,000 shares outstanding. The market capitalization of Immatics NV is $805.80 million. Immatics NV has a price to earnings ratio (PE ratio) of 21.48.

IMTX Latest News

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

         UNITED STATES  SECURITIES AND EXCHANGE COMMISSION  Washington, D.C. 20549   FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Table of Contents FILED PURSUANT TO RULE 424(B)(5)REGISTRATION NO. 333-258351   PROSPECTUS SUPPLEMENT (to Prospectus dated August 9, 2021)   IMMATICS N.V. 15,925,000...

Immatics Announces Pricing of $175 Million Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Table of Contents FILED PURSUANT TO RULE 424(B)(5)REGISTRATION NO. 333-258351   THE INFORMATION IN THIS PRELIMINARY PROSPECTUS SUPPLEMENT IS NOT COMPLETE AND MAY BE CHANGED. THIS...

Immatics Announces Proposed Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing PR Newswire COLOGNE, Germany and ZURICH, Jan. 16, 2024 Transformative surfaceome discovery...

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing PR Newswire COLOGNE, Germany and ZURICH, Jan. 16, 2024 Transformative surfaceome discovery...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.04-0.37914691943110.5512.3110.252369757511.26129456CS
4-1.99-15.9212.513.1610.252353752911.84871032CS
120.212.0388349514610.313.1610.2153615211.75156169CS
26-0.72-6.4113980409611.2313.167.1551221710.47766056CS
523.3646.9930069937.1513.165.946437110.52450206CS
156-1.75-14.274061990212.2616.35.7527064310.44761079CS
260-6.74-39.072463768117.25195.7529575611.10354096CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

IMTX Discussion

View Posts
Solarfuture Solarfuture 2 weeks ago
Thank u! Very interesting. I would like to see some higher levels in the PPS before something like M&A....
But perhaps interesting times coming...
👍️0
FACT-MASTER FACT-MASTER 2 weeks ago
IMTX: S/A Article of Interest:

https://seekingalpha.com/news/4077812-patent-cliffs-could-fuel-increased-ma-in-oncology-this-year-cantor-says

Cantor sees strong year ahead for oncology M&A
Mar. 10, 2024 12:08 PM ETKura Oncology, Inc. (KURA) Stock, BCYC Stock, IMCR Stock, ALXO Stock, CGON StockJNJ, NVS, BMY, PFE, MRK, EXEL, GERN, FUSN, VSTM, KPTI, SNDX, MRUS, URGN, DCPH, MOR, ARVN, HARP, IDYA, SWTX, RVMD, ORIC, ZNTL, LEGN, RLAY, IMTX, PMVP, OLMA, DAWN, JANX, AMAM, ERAS, NUVLBy: Val Brickates Kennedy, SA News Editor9 Comments
Chessboard with chess pieces and wooden blocks with the word mergers and acquisitions
cagkansayin

Cantor Fitzgerald sees another strong year ahead for oncology M&A, with companies focused on antibody drug conjugates, radiopharmaceuticals and T-cell engagers expected to attract increased attention from major drugmakers looking to replenish pipelines.

Impending patent cliffs will be a big motivator for deals. According to Cantor, around $182B in revenue is at risk over the next four years due to patent expirations, with oncology products accounting for 42% of that number.

Several of the industry's biggest are set to lose patent protection by 2029, including Bristol Myers (BMY) Yervoy, Pomalyst and Opdivo; Johnson & Johnson’s (JNJ) Imbruvica; Merck’s (MRK) Keytruda; Pfizer’s (PFE) Ibrance; and Roche’s (OTCQX:RHHBY) Perjeta, according to Cantor.

Meanwhile, the global market for oncology drugs is expected to grow from $180B in 2022 to $323B in 2028, a rate that is “unparalleled to other therapeutics areas,” Cantor said. In comparison, the global biopharmaceutical market is expected to swell from $978B in 2022 to $1.39T in 2028.

Cantor estimates the industry should see between five and 17 acquisition deals this year, noting that three have already been announced to date: J&J/Ambrx (AMAM), Merck/Harpoon (HARP), and Novartis (NVS)/Morphosys (MOR).

The investment bank also pointed out that the pool of potential buyers is fairly deep as pretty much every major drugmaker has a presence in oncology, with Novo Nordisk (NVO) being a notable exception.

So what type of assets will Big Pharma be seeking out?

Cantor still sees a preference for de-risked assets but noted that proof-of-concept data for oncology drugs can often be achieved in Phase 1/2 testing. Drug candidates addressing larger markets, such as breast, lung or colorectal cancer, should be particularly attractive to potential buyers.

While small molecule candidates will probably account for around 50% of the deals, Cantor says complex biologics have been gaining in popularity. The bank sees assets such as antibody drug conjugates, radiopharmaceuticals and T-cell engagers as being particularly attractive acquisition targets this year, while synthetic lethality and TCR therapies could also see increased interest.

Cantor sees several companies in its coverage universe as potentially attracting suitors this year, including Kura (NASDAQ:KURA), Bicycle (NASDAQ:BCYC), Immunocore (NASDAQ:IMCR), ALX Oncology (NASDAQ:ALXO), Arvinas (ARVN), Immatics (IMTX), Verastem (VSTM), Oric (ORIC), and CG Oncology (NASDAQ:CGON).

Potential targets outside of its coverage include Day One (DAWN), Deciphera (DCPH), Erasca (ERAS), Exelixis (EXEL), Fusion (FUSN), Geron (GERN), Ideaya (IDYA), Karyopharm (KPTI), Janux (JANX), Legend Biotech (LEGN), Merus (MRUS), Nuvalent (NUVL), Olmea (OLMA), PMV (PMVP), Relay Therapeutics(RLAY), Revolution Medicines (RVMD), Syndax (SNDX), SpringWorks Therapeutics (SWTX), UroGen (URGN), and Zentalis (ZNTL).
👍️0
Solarfuture Solarfuture 4 weeks ago
Chart looking much better now. IMO good chance to leave these levels now and climb to 20th...
👍️0
FACT-MASTER FACT-MASTER 1 month ago
I don't think there is a set timeline for FDA approval, once RMAT designation is received.

Combining RMAT with Accelerated Approval and Priority Review would greatly reduce the timeline for approval and to reach the market.

Article of Interest regarding RMAT:

https://www.pharmacytimes.com/view/regenerative-medicine-advanced-therapy-the-latest-special-fda-designation
👍️0
FACT-MASTER FACT-MASTER 1 month ago
I'm actually expecting a press release tomorrow morning. Day 2 = February 28/24

https://cartcr-europe.com/seminar/clinical-activity-of-ima203-tcr-t-targeting-prame-in-melanoma-beyond/

Tomorrow's session includes a clinical update on IMA 203

Interesting that they chose London to provide the clinical update.
👍️0
FACT-MASTER FACT-MASTER 1 month ago
imo,

today's session:

https://cartcr-europe.com/seminar/accelerating-analytical-testing-to-facilitate-rapid-product-release-decrease-end-to-end-production-time/
would probably be in reference to their manufacturing facility in Houston.


Remember they received RMAT designation for IMA203 - announced October24/23.

https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/92348626/immatics-receives-fda-regenerative-medicine-advanc

They never announced an IND enabling Phase 2 trial yet. No updates since October 25/23

https://classic.clinicaltrials.gov/ct2/history/NCT03686124?A=1&B=22&C=merged#StudyPageTop
👍️0
Solarfuture Solarfuture 1 month ago
New data should come soon:

New Clinical Data From:

IRCCS Bambino Gesu Children’s Hospital, Immatics, Caribou Biosciences, Carisma Therapeutics, and Kyverna Therapeutics

https://cartcr-europe.com/

February 27-29, 2024
👍️0
Hungry_Ghost Hungry_Ghost 1 month ago
Hello
👍️0
FACT-MASTER FACT-MASTER 1 month ago
StemPoint Capital LLC - new investor of interest

https://www.businesswire.com/news/home/20230119005659/en/StemPoint-Capital-Announces-Strategic-Relationship-with-Leucadia-Asset-Management

https://leucadia-am.com/investment_offerings/stempoint-capital/
👍️0
FACT-MASTER FACT-MASTER 1 month ago
IMTX: Institutional Holdings for Dec.31/23 just starting to come in:

Significant increases to date, at Wellington / Woodline / Goldman Sachs / Stempoint - new investor/ complete listing here:

https://www.nasdaq.com/market-activity/stocks/imtx/institutional-holdings
👍️0
Solarfuture Solarfuture 2 months ago
Novartis wants to buy Morphosys...
Interesting is - Immatics and Morphosys and Novartis seem to have connections, too.
Perhaps it's only the beginning of a bigger consolidation in the sector.

https://www.labiotech.eu/trends-news/leading-german-biotechs-morphosys-and-immatics-partner-to-pump-up-their-immuno-oncology-therapies/

Sectors
Drug Development
More
Podcast
Reports
Home News and Trends
Leading German Biotechs MorphoSys and Immatics partner to pump up their Immuno-Oncology Therapies
By Philip Hemme
2 mins
August 25, 2015
Updated
:
August 4, 2021
Two German biotechs with highly successful platforms join forces to fight cancer. MorphoSys and Immatics Biotechnologies want to generate novel antibody-based therapeutics against multiple cancer antigens.

They are two of the thriving forces in the German biotech scene. Munich’s MorphoSys claims having developed the most successful antibody library technology in the pharma industry, currently has 100 distinct drugs in research and development and is worth €1.67Bn. Tübingen-based Immatics owns the leading target discovery platform in cancer immunotherapy and raised over €120M. And now they want to team up. What a match!

Here’s how they want to tackle cancer: Tumor cells contain specific peptides that are not present in healthy cells. These are presented on the surface through specialized receptors, so-called major histocompatibility complex (MHC) receptors. The collaboration between Immatics and MorphoSys aims to discover antibodies against these MHC-bound peptide targets in order to kill the tumor cells.

Within the collaboration, MorphoSys gets several tumor-associated peptides that were discovered using Immatics’ platform. These are present in a number of solid and hematological cancers and can be used as antibody targets.

In return, Immatics will be provided with some of MorphoSys’ antibodies against a number of its discovered peptides. The companies will pay each other undisclosed milestones as well as royalties on marketed products.

The partnering is especially valuable for MorphoSys. It had to sustain a major drop of its stock after Celgene had abandoned the company. Since then, both collaborations with Novartis and Heptares Therapeutics advanced. With all these good news, MorphoSys stock slowly recovers.

The merging could pave the way for a leading immuno-oncology player, from which the whole biotech ecosystem could profit.

Bonus, we interviewed the CEO of Immatics Paul Higham during our South German Tour. Here’s the video:

Please accept cookies to access this content


Immatics – Paul Higham, CEO from LabiotechTour on Vimeo.
👍️0
Solarfuture Solarfuture 2 months ago
Interesting!
Think ist's important now to leave the 52 week range and to climb about 13.14....after that it could quickly go to 15 and more...
👍️0
FACT-MASTER FACT-MASTER 2 months ago
IMTX: Options activity of interest:

Sizeable open interest on Feb 16 calls with strike price of $15 and $17.5 as a point of information.

(unable to post chart)
👍️0
FACT-MASTER FACT-MASTER 2 months ago
IMTX: Presentation February 11-14 at SCOPE 24

https://investors.immatics.com/events-presentations

https://www.scopesummit.com
👍️0
Solarfuture Solarfuture 2 months ago
Thanks! Everything looking promising here. Hope some big Investors will soon come in...
👍️0
FACT-MASTER FACT-MASTER 2 months ago
BIOTECHTV video : TCR discussion starts around 15:30 mark of this video - Cantor Fitzgerald

https://www.biotechtv.com/post/eric-schmidt-cantor-fitzgerald-january-22-2024
👍️0
FACT-MASTER FACT-MASTER 2 months ago
IMTX: New Presentation - January 22, 2024 ( filed as an exhibit)

https://www.sec.gov/Archives/edgar/data/1809196/000095010324000955/dp205494_ex9903.htm
👍️0
FACT-MASTER FACT-MASTER 2 months ago
IMTX: Sec filing regarding recent offering / capital raise - interesting exhibits

https://www.sec.gov/Archives/edgar/data/1809196/000095010324000955/dp205494_6k.htm
👍️0
FACT-MASTER FACT-MASTER 2 months ago
This puts the O/S (Outstanding Shares) in and around 100 million.

Theory = Internal squabbling and IMTX is buying out dissenting shareholders.
👍️0
FACT-MASTER FACT-MASTER 2 months ago
IMTX: Immatics Announces Pricing of $175 Million Public Offering

https://www.globenewswire.com/news-release/2024/01/18/2811206/0/en/Immatics-Announces-Pricing-of-175-Million-Public-Offering.html

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $175 million. The offering is expected to close on January 22, 2024, subject to customary closing conditions. In addition, Immatics has granted the underwriters a 30-day option to purchase up to 2,388,750 additional shares at the public offering price, less the underwriting discount.

Jefferies, BofA Securities and Leerink Partners are acting as joint book-running managers for the offering.

A registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective on August 9, 2021. The offering is being made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained free of charge from

Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 821-7388, email: Prospectus_Department@Jefferies.com;
BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, telephone: (800) 294-1322, email: dg.prospectus_requests@bofa.com;
Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: (800) 808-7525, ext. 6105, email: syndicate@leerink.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
👍️0
FACT-MASTER FACT-MASTER 2 months ago
IMTX: recent short report:

https://www.marketbeat.com/stocks/NASDAQ/IMTX/short-interest/

2 million plus increase in short position December 15/23 - December 31/23

"Thanks".... IMTX management
👍️0
FACT-MASTER FACT-MASTER 2 months ago
IMTX: https://www.sec.gov/Archives/edgar/data/1809196/000119312524009253/d127760d424b5.htm#supptoc127760_6

Not sure what to think of this. Biggest question, at the moment imo, is why the capital raise when they have enough cash on hand and just received 120 million from Moderna?

Probably tanking tomorrow.
👍️0
Solarfuture Solarfuture 3 months ago
Interesting find! It seem's to me something will happen here in the near future...
👍️0
Solarfuture Solarfuture 3 months ago
Nice volume again!
👍️0
FACT-MASTER FACT-MASTER 3 months ago
January 9/25 3:07 ET Level II Ask looking thin, at the moment, especially above $12.25
👍️0
FACT-MASTER FACT-MASTER 3 months ago
Volume/Price - on FIRE!!

Sumthing go'ing on at JP Morgan conference??
👍️0
FACT-MASTER FACT-MASTER 3 months ago
IMTX: Clinical Trial Review:

1. NCT05958121 IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/?or Refractory Solid Tumors
https://clinicaltrials.gov/study/NCT05958121?spons=immatics&rank=3&tab=table

2. NCT05359445 IMA401 TCER® in Recurrent and/?or Refractory Solid Tumors
https://clinicaltrials.gov/study/NCT05359445?spons=immatics&rank=4&tab=table

3. NCT03686124 ACTengine® IMA203/?IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/?or Refractory Solid Tumors (ACTengine)
https://clinicaltrials.gov/study/NCT03686124?spons=immatics&rank=6&tab=table

Of interest is that all 3 have Data Monitoring Committees

https://www.ppd.com/wp-content/uploads/2020/07/decision-tree-graphic.pdf
👍️0
FACT-MASTER FACT-MASTER 3 months ago
IMTX: Immatics to attend meetings at the 42nd Annual J.P. Morgan Healthcare Conference January 8-11/24

https://investors.immatics.com/events-presentations
👍️0
Solarfuture Solarfuture 4 months ago
Immatics Announces Third Quarter 2023 Financial Results and Business Update...
👍️0
Solarfuture Solarfuture 5 months ago
8.30 am conference call....
👍️0
FACT-MASTER FACT-MASTER 5 months ago
IMTX: Form 6-k

https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/92498872/form-6-k-report-of-foreign-issuer-rules-13a-16

EXCERPT 1:


Development path for IMA203 GEN1 and IMA203CD8 GEN2 monotherapies



The goal of Immatics’ development strategy is to make its cell therapies targeting PRAME available to the broadest possible solid cancer patient population with an initial focus on the US market. To achieve this, Immatics has announced a three-step development strategy for leveraging the full breadth of PRAME, a target that is highly expressed in various solid cancers.



1. Focus on IMA203 GEN1 in cutaneous melanoma (potentially bundled with uveal melanoma), targeted to enter a registration-enabling Phase 2 clinical trial in 2024. Discussions with FDA to align on patient population, clinical trial design and CMC aspects are ongoing under the RMAT designation achieved for IMA203 GEN1 in multiple cancer types including cutaneous and uveal melanoma. There are up to 3,300 HLA-A*02 and PRAME-positive cutaneous and


Immatics Press Release November 8, 2023 5 | 8


uveal melanoma last-line patients per year in the US. A next update on the clinical development plan is expected in the first quarter of 2024.



2. In parallel, commence dedicated dose expansion cohorts for signal finding in ovarian and uterine cancer, preferentially with IMA203CD8 GEN2. Enrollment of patients with these cancer types is already ongoing. There are up to 9,000 HLA-A*02 and PRAME-positive ovarian and uterine last-line cancer patients per year in the US.


3. The development of a broader tumor-agnostic label in PRAME+ solid cancers, including in NSCLC, triple-negative breast cancer, and others. This could leverage the full potential of PRAME across multiple solid cancer types.
👍️0
FACT-MASTER FACT-MASTER 5 months ago
IMTX: Press Release Nov.8/23

https://finance.yahoo.com/news/immatics-reports-interim-clinical-data-120000187.html
👍️0
Solarfuture Solarfuture 5 months ago
Interim clinical data out...
👍️0
Solarfuture Solarfuture 5 months ago
Thank u! Seems to have the knowledge in the sector...
Hope to see another nice day with buying pressure...
👍️0
FACT-MASTER FACT-MASTER 5 months ago
IMTX: New analyst coverage from Cantor Fitzgerald.

https://www.streetinsider.com/New+Coverage/Cantor+Fitzgerald+Starts+Immatics+%28IMTX%29+at+Overweight/22349384.html?classic=1

Articles on Eric Schmidt:

https://endpts.com/former-allogene-cfo-eric-schmidt-talks-about-his-new-role-at-cantor-and-the-future-of-cell-therapies/

https://biotuesdays.com/2023/09/06/cantor-boosts-biotech-research-with-josh-schimmer-eric-schmidt/

( all are subscription articles)
👍️0
Solarfuture Solarfuture 5 months ago
I agree. Within the next days/weeks we should hear something.
That would be great. In that case we would quickly climb above 50 and more...
👍️0
FACT-MASTER FACT-MASTER 5 months ago
I concur, sentiment reversal with buying pressure now.

According to the latest presentation, should be a clinical update in Q4/23 in IMA203 - ref. page 27

https://investors.immatics.com/static-files/0df36fcf-308b-4e29-afe7-c83c562abab6

Also, if you put the latest press release regarding RMAT designation for IMA203 into the context of the above presentation, FDA approval of IMA203 is a possibility in 2024, imo.
( that could be taken as a bold statement, however, imo IMTX is doing an awesome job in all departments.)

RMAT Press Release:
https://investors.immatics.com/news-releases/news-release-details/immatics-receives-fda-regenerative-medicine-advanced-therapy-0
👍️0
Solarfuture Solarfuture 5 months ago
Nice to see.Selling pressure seems to bei over....
👍️0
FACT-MASTER FACT-MASTER 5 months ago
IMTX Nov.3/23: Closed at $9.61 + $1.43 on 1,179,110 shares traded
👍️0
FACT-MASTER FACT-MASTER 5 months ago
Gett'in some luv here the past few days - but especially today!

Last at $9.27 + $1.09
Volume 711,357
👍️0
FACT-MASTER FACT-MASTER 5 months ago
That possibility crossed my mind as well.

However, looking at the trend in institutional selling, ie WELLINGTON/SOFINNOVA /NANTAHALA at June 30, and if that trend continued past June 30/23 ( as it appears that it has, and judging by the selling pressure sine June 30/23), this has me concerned that it is more then one seller unloading.

https://www.nasdaq.com/market-activity/stocks/imtx/institutional-holdings

One POSITIVE, from that list though, is that Baker added to their position, that instills some confidence in IMTX, imo.

Of course Nasdaq is only updated to June 30/23, so it could be considered old news.

Looking for more current institutional holdings.
👍️0
Solarfuture Solarfuture 5 months ago
This prospectus relates to the offer and sale from time to time by Bristol-Myers Squibb Company (the “selling securityholder”) of up to 2,419,818 of our ordinary shares, €0.01 nominal value per share. This prospectus also covers any additional securities that may become issuable by reason of share splits, share dividends or other similar transactions...

I think this is the reason....I believe they don't like the deal with Moderna and sell shares...
👍️0
FACT-MASTER FACT-MASTER 5 months ago
I agree, patience is key here.

All the news of collaborations/RMAT/limited data have been positive. Not understanding the stock price moves.

I've been watching for institutional share disclosures to see if an institution has been unloading, but haven't seen anything thus far.
Will post if i find anything.
👍️0
Solarfuture Solarfuture 5 months ago
I can't understand the PPS. The news was huge, I agree.
I think we have to be patient. If they go their way we'll see totally different courses here. In a view years I would not bet against a range of 50 to 100 dollars here....
👍️0
FACT-MASTER FACT-MASTER 5 months ago
IMA203 = Immatics proprietary

https://immatics.com/our-pipeline/

More data on IMA203 should be disclosed, imo.
👍️0
FACT-MASTER FACT-MASTER 5 months ago
IMTX: RMAT advantages - a few (albeit older) articles of interest:

https://www.insights.bio/cell-and-gene-therapy-insights/journal/article/308/Breakthrough-Therapy-Designation-Regenerative-Medicine-Advanced-Therapy-Designation-Programs-in-Cellular-Gene-Therapies

https://www.raps.org/News-and-Articles/News-Articles/2018/2/RMAT-vs-Breakthrough-vs-Fast-Track-Companies-Se

https://www.pharmacytimes.com/view/regenerative-medicine-advanced-therapy-the-latest-special-fda-designation
👍️0
FACT-MASTER FACT-MASTER 5 months ago
IMTX: Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

https://www.sec.gov/Archives/edgar/data/1809196/000095010323015263/dp201755_6k.htm

HUGE news , imo
👍️0
FACT-MASTER FACT-MASTER 6 months ago
IMTX: Immatics presenting at AACR-NCI-EORTC international conference

https://investors.immatics.com/events/event-details/immatics-presenting-aacr-nci-eortc-international-conference

https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2/program/#Con1
👍️0
Monksdream Monksdream 7 months ago
IMTX new 52 week high
👍️0
FACT-MASTER FACT-MASTER 7 months ago
IMTX: Moderna Collaboration

https://fintel.io/doc/sec-immatics-nv-1809196-6k-2023-september-11-19611-8721?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing


INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K



On September 7, 2023, Immatics Biotechnologies GmbH, a subsidiary of Immatics N.V. (the “Company” or “Immatics”), entered into a Master Collaboration and License Agreement (the “Master Collaboration and License Agreement”) with ModernaTX, Inc., a subsidiary of Moderna, Inc. (“Moderna”), relating to three research programs for the development and commercialization of products employing Immatics’ and Moderna’s technologies: (i) a collaboration to discover and develop mRNA-based TCER therapeutics against targets of interest to Moderna (the “TCER Program”); (ii) the validation, generation and application of data useful for the research and development of cancer vaccines (the “Database/Vaccine Program”); and (iii) a combination therapy clinical trial with respect to IMA203 and a Moderna mRNA-based cancer vaccine (the “Clinical Combo Program”). Each research program will be governed by the Master Collaboration and License Agreement and a project agreement as described below.



Pursuant to the Master Collaboration and License Agreement, following Hart-Scott-Rodino Antitrust Improvements Act clearance, Moderna will pay to Immatics a $120 million upfront payment. In addition, as described below, Immatics may be eligible to receive development, regulatory and commercial milestone payments that could exceed $1.7 billion.



With respect to the TCER Program, pursuant to the Master Collaboration and License Agreement and the TCER Collaboration Project Agreement between the parties (the “TCER Project Agreement”), the parties will conduct the TCER Program for the research and development of TCERs with respect to HLA-presented peptide targets derived from an agreed upon number of proteins selected by Moderna. Immatics will be responsible for, and be reimbursed the cost of, TCER identification, validation and engineering to generate the applicable TCER sequence and preclinical studies in accordance with the applicable mutually agreed research plan, while Moderna will be responsible for, and bear the cost of, developing, manufacturing and commercializing the applicable products containing or comprising such TCERs; provided that Immatics has a right to co-fund the development and commercialization of certain products by making an opt-in payment in exchange for profit and loss sharing on such products. Immatics will grant to Moderna an exclusive, worldwide sublicensable license to develop, manufacture and commercialize any product (or that contain any product) developed under the TCER Project Agreement. For each target, depending on certain product characteristics, Immatics may be eligible to receive milestone payments of up to a mid-eight-digit amount upon the achievement of certain development milestones and up to a mid-nine-digit amount upon the achievement of certain regulatory and commercial milestones. In addition, during the royalty term (as described below) and depending on certain product characteristics, Immatics will be eligible to receive tiered, mid-single-digit to low-double-digit percentage royalties on worldwide net sales of the applicable product, which royalty percentages are subject to reduction in a given country under certain circumstances. A royalty term with respect to a product under the TCER Program in a given country begins upon the first commercial sale of such product in such country and terminates on the latest of the expiration of regulatory exclusivity, the expiration of valid patent claims covering such product, and 10 years after first commercial sale of the product in a given country. The TCER Project Agreement will expire upon expiration of the last royalty term contemplated by the TCER Project Agreement. During the term of the TCER Program, Immatics has certain exclusivity and notification obligations to Moderna, and its ability to develop, manufacture and commercialize certain cell therapy products that bind to the targets subject to the TCER Project Agreement is limited by the TCER Project Agreement.



With respect to the Database/Vaccine Program, pursuant to the Master Collaboration and License Agreement and the Database/Vaccine Collaboration Project Agreement between the parties (the “Database/Vaccine Project Agreement”), the parties will use Immatics’ XPRESIDENT platform to (i) generate reports for proteins or cancer vaccine candidates and validate cancer vaccine candidates (the “Database Query Program”), (ii) select peptides for respect to specific tumor types selected by Moderna for the development of cancer vaccines (the “Shared Vaccine Program”), and (iii) provide certain epitope prediction data for potential development and validation of cancer vaccines (the “Optimized Vaccine Program”). The term of these programs can be up to approximately five years. Immatics will grant to Moderna an exclusive, worldwide sublicensable license to develop, manufacture and commercialize any Shared Vaccine product or Optimized Vaccine product developed under the Database/Vaccine Project Agreement. Immatics may be eligible to receive (i) depending on the characteristics of the cancer vaccine, certain milestone payments under the Database Query Program, (ii) for each resulting cancer vaccine in the Shared Vaccine Program and the Optimized Vaccine Program, depending on certain product characteristics, up to a low-eight-digit amount upon the achievement of certain development milestones and up to a low-nine-digit amount upon the achievement of certain regulatory and commercial milestones, and (iii) for each resulting cancer vaccine in the Shared Vaccine Program, during the royalty term (as described below) and depending on certain product characteristics, tiered, low- to mid-single-digit percentage royalties on worldwide net sales of such product. A royalty term with respect to a cancer vaccine in the Shared Vaccine Program and the Optimized Vaccine Program in a given country begins upon the first commercial sale of such product in such country and







terminates on the latest of the expiration of regulatory exclusivity, the expiration of valid patent claims covering such product, and 10 years after first commercial sale of the product in a given country. During the term of the Database/Vaccine Program, Immatics has certain exclusivity obligations to Moderna, and its ability to develop certain cancer vaccines is limited by the Database/Vaccine Project Agreement.



With respect to the Clinical Combo Program, pursuant to the Master Collaboration and License Agreement and the Combination Collaboration Project Agreement between the parties (the “Clinical Combo Project Agreement”), the parties will collaborate to develop a combination therapy of IMA203 (or IMA203CD8) and a Moderna mRNA-based cancer vaccine. Immatics will be responsible for, and the parties will share the cost of, development activities in accordance with the applicable mutually agreed research plan. For so long as the parties are conducting the combination therapy clinical trial, Immatics has certain exclusivity obligations to Moderna, and its ability to develop, manufacture and commercialize combination products that involve a cancer vaccine and a cell therapy product that binds to the target of IMA203 is limited by the Clinical Combo Project Agreement.



The foregoing descriptions of the Master Collaboration and License Agreement and the project agreements thereunder do not purport to be complete and are qualified in their entirety by reference to the full text of the applicable agreements, which will be filed as an exhibit to the Company’s Annual Report on Form 20-F for the year ended December 31, 2023 or a Report on Form 6-K.



In connection with the foregoing, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.1, and made available an updated investor presentation on its website, a copy of which is attached hereto as Exhibit 99.2.



INCORPORATION BY REFERENCE



This Report on Form 6-K (other than Exhibit 99.1 and 99.2 hereto) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-258351, 333-240260 and 333-274218) of Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
👍️0

Your Recent History

Delayed Upgrade Clock